Medical/Pharmaceuticals

Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs

SUZHOU, China, July 6, 2023 /PRNewswire/ -- GeneQuantum Healthcare, a leader in the innovative bioconjugation technologies for ADC new drug development, announced the expansion of its partnership with a South Korean biotech company Aimed Bio today. This strategic collaboration aims to jointly dev...

2023-07-07 10:19 2635

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment

SHANGHAI, July 6, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the completion of patient enrollment for...

2023-07-06 18:33 2656

Genesis MedTech Receives Approval for Launch in China for ArtiSential™

SINGAPORE, July 6, 2023 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced that its ArtiSential™, a revolutionary series of articulating laparoscopic instruments, has successfully obtained approval from theChina's National Medical Products Administration (NMPA) for...

2023-07-06 18:00 3266

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China

SUZHOU, China and ROCKVILLE, Md., July 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of the Chi...

2023-07-06 10:38 2473

United Imaging, Kicking off a Birthday Celebration of Five Years in the U.S. Market, Will Debut Three New Scanners at AHRA

Following on the heels of the unveiling of the uMI Panorama™ at SNMMI's annual meeting this week, United Imaging confirmed it will officially debut three additional new products in MRI, CT, and X-ray in July inIndianapolis and enter its second year of the Leaders of Choice program it sponsors wit...

2023-07-06 00:00 2825

Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development

NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment ofFurqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible fo...

2023-07-05 22:05 3026

Lunit Makes Full-Fledged Entry into the Middle East with Participation in 'Saudi Vision 2030' Healthcare Transformation Project

* Lunit's AI-powered cancer screening solutions have been selected for Seha Virtual Hospital's AI evaluation and clinical integration project * Successful validation to be followed by supply contract to assist Saudi Arabia's national cancer and tuberculosis screening program SEOUL, South Korea...

2023-07-05 21:00 2962

PENTAX MEDICAL ANNOUNCES THE APPOINTMENT OF DAVID HARRISON AS THE NEW PRESIDENT FOR THE AMERICAS

MONTVALE, N.J., July 5, 2023 /PRNewswire/ -- PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy, is pleased to announce the appointment ofDavid Harrison as President of the Americas. Effective July 1, 2023, Mr. Harrison assumed the role of President following th...

2023-07-05 21:00 2664

TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

-  Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist inChina -  TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis inEurope by the end of the year BOSTON and SEONGNAM, South Korea, July 5, 2023 /P...

2023-07-05 20:00 3704

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering  immunotherapies, today announced the publication of a manuscript entitled "C...

2023-07-05 20:00 2628

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evalu...

2023-07-04 21:16 3359

Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer

Highlights * FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer  * Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial * A total of 383 prostate cancer patients to take part ...

2023-07-04 20:55 3388

China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy

 -- pitolisant is the first and only treatment drug approved in mainland China for narcolepsy.  SHANGHAI, July 4, 2023 /PRNewswire/ -- RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chinese National Med...

2023-07-04 20:42 2476

Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology

- Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists' chest X-ray analysis performance SEOUL, South Korea, July 3, 2023 /PRNewswire/ -- Findings from a recent study demonstrate that medical AI solutions with onl...

2023-07-03 21:00 3481

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration

SHANGHAI and BOSTON, July 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...

2023-07-03 19:00 2433

Henlius Forecasts Profit in 1H 2023

Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...

2023-07-03 17:49 3164

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease

SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health ...

2023-07-03 08:00 3551

Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally

* Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials inChina. * BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications overseas and clinical trial materials supply. SHANGHAI, Ju...

2023-06-30 20:15 3802

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 29, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2023-06-29 21:26 3382

HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial

* Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%). * Significant overall survival advantage, with a 46% reduction in the risk of death. * Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further Kap...

2023-06-29 19:00 3040
1 ... 171172173174175176177 ... 262